Set in early 2021, this case is about Kino Biotech, a Singapore-based company producing health and beauty products, most notably its flagship brand, Kinohimitsu. Its operations and distribution have expanded globally, especially to Malaysia, Indonesia, and China. In April 2018, Kino Biotech launched a spin-off company called Kinofy to leverage its cross-border commerce license and digital business experience of operating in China. Kinofy provides consulting solutions to Singapore and international companies that want to enter China. Kinofy is also pivotal in building a cross-border e-commerce platform where the collective intelligence can be accumulated when more Singapore and international firms enrol.

By following the journey of Kino Biotech and Kinofy from their start and through several critical transformations across three decades, this case enables a rich discussion on how firms manage strategic change, internationalisation, and digital transformation.